Phase 2 study of Letrozole-ISM vs Femara
Latest Information Update: 08 May 2023
At a glance
- Drugs Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
Most Recent Events
- 25 Apr 2023 According to Rovi media release, in the light of the advice received from the FDA, the clinical development that would foreseeably be required to obtain marketing authorisation (at least in the United States) for the annual formulation of Letrozole ISM would entail this phase 2 and, subsequently, a Phase 3 trial in women with early breast cancer.
- 02 Mar 2023 New trial record